CurrentBlue Cross Blue Shield - TennesseePolicy N/A

Testing for Mosquito- or Tick-Related Infections — Coverage Criteria

Defines coverage and reimbursement criteria for laboratory testing (culture, microscopy, NAAT/PCR, and serology) for various mosquito- and tick-borne infections for Blue Cross Blue Shield - Tennessee members. Applies to diagnostic testing decisions for suspected arboviral, rickettsial, protozoan, and other vectorborne diseases.

Policy Summary

PayerBlue Cross Blue Shield - Tennessee

PolicyTesting for Mosquito- or Tick-Related Infections — Coverage Criteria

Policy CodePolicy N/A

Change TypeNo material changes

Effective DateJul 1, 2023

Next Review DateN/A

Key ActionSelect diagnostic tests by pathogen and specimen type and document specimen timing and clinical signs to support coverage.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

17+coverage statements

up to 3xmalaria smear repeats allowed

2 unitsIFA IgG unit limit

early PCRPCR preferred early

6,248RMSF cases cited (2017)

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Coverage Determinations and Diagnostic Guidance

Enumerated Coverage Determinations

Coverage determinations by suspected condition:

Rickettsial disease - IgG IFA: For individuals suspected of having a rickettsial disease, use of an indirect immunofluorescence antibody (IFA) assay for IgG antibodies (limited to two units) MEETS COVERAGE CRITERIA.IFA IgG limited to two units

See Note 1 for clinical signs/symptoms

Rickettsial disease - IgM/NAAT/culture: For individuals suspected of having a rickettsial disease, the use of standard blood culture, nucleic acid amplification testing (NAAT) including PCR, or IFA assay for IgM antibodies DOES NOT MEET COVERAGE CRITERIA.

Ehrlichiosis/Anaplasmosis - NAAT/IgG/microscopy: For individuals suspected of having ehrlichiosis and/or anaplasmosis, the use of NAAT (including PCR) of whole blood, IFA assay for IgG antibodies, or microscopy for morulae detection MEETS COVERAGE CRITERIA.

See Note 2 for clinical signs/symptoms

Ehrlichiosis/Anaplasmosis - IgM/culture: For individuals suspected of having ehrlichiosis and/or anaplasmosis, the use of an IFA assay for IgM antibodies or standard blood culture DOES NOT MEET COVERAGE CRITERIA.

Tick-borne relapsing fever (TBRF) - microscopy/PCR/IgG IFA: For individuals suspected of having TBRF, the use of darkfield microscopy of a peripheral blood smear, Wright- or Giemsa-stained blood smear microscopy, PCR testing, or IFA for IgG for Borrelia MEETS COVERAGE CRITERIA.

See Note 3

TBRF - IgM/culture: For individuals suspected of having TBRF, the use of an IFA assay for IgM for Borrelia or culture testing for Borrelia DOES NOT MEET COVERAGE CRITERIA.

Babesiosis - smear/NAAT: For individuals suspected of having babesiosis, the use of a Giemsa- or Wright-stain of a blood smear or NAAT (including PCR) MEETS COVERAGE CRITERIA.

See Note 4

Babesiosis - IFA IgG/IgM: For individuals suspected of having babesiosis, the use of either an IgG or IgM IFA assay for Babesia DOES NOT MEET COVERAGE CRITERIA.

Malaria - smear/RDT: For individuals suspected of having malaria, the use of a rapid immunochromatographic diagnostic test (RDT) or smear microscopy to diagnose malaria, determine Plasmodium species, identify life-cycle stage, and/or quantify parasitemia MEETS COVERAGE CRITERIA; smear microscopy may be repeated up to three times within three days if initial microscopy is negative in suspected cases.<=3 repeats within 3 days

See Note 5

Malaria - NAAT/IFA: For individuals suspected of having malaria, the use of NAAT (including PCR) or IFA for Plasmodium antibodies DOES NOT MEET COVERAGE CRITERIA.

Chikungunya - culture/NAAT/IgM: For individuals suspected of having chikungunya virus, the use of viral culture, NAAT (including PCR) on serum, or IFA assay for IgM antibodies during acute and convalescent phases MEETS COVERAGE CRITERIA.

See Note 6

West Nile Virus - IgM/PRNT: For individuals suspected of having West Nile Virus, the use of IFA for WNV-specific IgM antibodies in serum or CSF and a confirmatory plaque reduction neutralization test (PRNT) for WNV MEETS COVERAGE CRITERIA.

See Note 7

West Nile Virus - NAAT/IgG: For individuals suspected of having WNV, the use of NAAT (including PCR) for WNV or IFA for WNV-specific IgG antibodies in serum or CSF DOES NOT MEET COVERAGE CRITERIA.

Yellow fever - NAAT/serology/PRNT: For individuals suspected of having yellow fever virus, the use of NAAT (including PCR) for YFV, serologic assays to detect virus-specific IgM and IgG antibodies, and a confirmatory PRNT for YFV MEETS COVERAGE CRITERIA.

See Note 8

Dengue - NAAT/NS1/MAC-ELISA/PRNT: For individuals suspected of having dengue virus, the use of NAAT (including PCR), IgM antibody capture ELISA (MAC-ELISA), or NS1 ELISA, and a confirmatory PRNT MEETS COVERAGE CRITERIA.

See Note 9

Dengue - IgG/HAI: For individuals suspected of having dengue, the use of IgG ELISA or hemagglutination inhibition testing DOES NOT MEET COVERAGE CRITERIA.

Colorado tick fever - IFA: For individuals suspected of having Colorado tick fever, the use of virus-specific IFA-stained blood smears or IFA for CTF-specific antibodies MEETS COVERAGE CRITERIA.

See Note 10

Organism‑specific diagnostic coverage

Covered diagnostic approaches vary by pathogen and specimen source; follow organism‑specific recommendations:

Rickettsial diseases: Prefer PCR on eschar biopsy or rash biopsy for Rickettsia parkeri and Rickettsia species 364D; whole blood PCR may be indicated for Rickettsia rickettsii but is less sensitive than tissue PCR; IFA (acute and convalescent IgG) is recommended for serologic confirmation.

Based on CDC recommendations; prefer tissue PCR for many spotted fever group rickettsiae.

Ehrlichiosis/Anaplasmosis: Perform PCR/NAAT on whole blood during the first week for Ehrlichia chaffeensis and related species; peripheral blood smear for intraleukocytic morulae can be diagnostic; IFA/ELISA serology is an alternative for acute/convalescent comparison.PCR within first week

Timing: symptoms typically 1-2 weeks after bite

Borrelia (relapsing fever): Use blood smear during febrile episode (darkfield or stained smears) and PCR (blood, CSF, tissue); serology showing seroconversion or new IgG in convalescent sample supports diagnosis; GlpQ antibody testing can help differentiate relapsing fever species from B. burgdorferi.

Organism-specific diagnostic criteria

Diagnostic approaches by organism group (covered when clinically indicated and specimens collected per recommendations):

Rickettsial diseases (e.g., RMSF): IFA serology (acute and convalescent) is the standard reference; obtain an acute specimen early and a convalescent specimen 2–4 weeks later; a ≥4-fold rise in titer confirms acute infection. PCR of whole blood has low sensitivity except in severe RMSF; skin/eschar biopsy PCR or NAAT and immunohistochemistry on tissue are useful when available.4-fold rise

IFA insensitive first week; use paired samples

Ehrlichiosis and Anaplasmosis: Perform PCR/NAAT on whole blood during the first week of illness; microscopy for morulae detection on blood smear or buffy coat may be indicative; acute and convalescent IFA titers for IgG can be used for serologic confirmation.N/A

PCR preferred early; doxycycline reduces PCR sensitivity

Tick-borne relapsing fever (TBRF):

Diagnostic approach and timing

Clinical diagnostic guidance summarized from referenced sources (AAP Red Book, IEC, CDC):

Arboviral diagnosis general: For most arboviruses, serologic testing (IgM and/or IgG) of serum and CSF is preferred because viremia is often low or transient; paired acute and convalescent sera (approximately 2–3 weeks apart) to document seroconversion or a fourfold rise are recommended when feasible.paired sera 2–3 weeks apart when possible

IEC and AAP guidance; arboviral IgM may persist and cross-react

When molecular/antigen testing is appropriate: RT-PCR or antigen tests (e.g., dengue NS1, chikungunya RT-PCR) are appropriate early in illness (typically first week after symptom onset) when viremia is present; WNV PCR is generally not recommended in immunocompetent patients because RNA is often undetectable by symptom onset but may be useful in immunosuppressed patients or very early disease.first week after symptom onset for RT-PCR/NS1

AAP and IEC references

Rickettsial and Anaplasmataceae testing timing:

The policy lists specific testing modalities that DO NOT MEET COVERAGE CRITERIA for certain suspected conditions. Examples include: IFA assay for IgM antibodies, standard blood culture, and NAAT/PCR for some rickettsial conditions (see rickettsial statements); IFA (IgG or IgM) and NAAT/PCR for Plasmodium (malaria); and IFA (IgG or IgM) for Babesia. These disallowed methods are enumerated within the reimbursement determinations and should not be used as the sole diagnostic basis when evaluating claims for the listed vectorborne infections.

The policy cautions against reliance on IgM serology alone for Rocky Mountain spotted fever (RMSF) and other spotted fever group rickettsiae because of limited specificity and potential false-positive results. The CDC guidance summarized in the policy emphasizes that IFA assays are insensitive during the first week of illness and that diagnosis generally requires paired acute and convalescent samples with demonstration of a fourfold rise in IgG titer for confirmation rather than a single IgM result.

Elevated antibody titers from a single specimen are not sufficient to diagnose acute rickettsial infection; confirmation requires paired acute and convalescent sera showing at least a fourfold rise in IgG titer. The policy also notes that rickettsiae are obligate intracellular organisms and cannot be isolated by standard blood culture techniques, so culture is not routinely used for rickettsial diagnosis and is listed as not meeting coverage criteria where specified.

For West Nile virus (WNV), the policy states that PCR/NAAT is generally not recommended for diagnosis in immunocompetent patients because WNV RNA is usually no longer detectable by the time symptoms begin. Serologic testing for anti-WNV IgM in serum or CSF is the primary diagnostic approach, with PRNT used for confirmatory testing or to resolve flavivirus cross-reactivity; NAAT may be appropriate in immunocompromised patients or in select early cases.

References supporting the diagnostic recommendations and the policy text are listed in the excerpt, and the policy adoption effective date is 7/1/2023 (adopted from an Avalon policy recommendation). The reference list includes CDC, AAP Red Book, IEC, peer-reviewed studies, and other clinical sources cited in the document.

The policy makes clear that use of tests identified as disallowed in the enumerated reimbursement statements is considered not meeting coverage criteria. Claims based on those methods (for example, NAAT/PCR for malaria or IFA IgM for rickettsial diseases where listed) may be denied unless clinical documentation supports an alternative covered approach.

The policy flags use of rapid antigen tests (such as BinaxNOW) as potentially insufficient when used as the sole diagnostic in non‑endemic settings due to reported lower sensitivity and misclassification risk. The document references studies showing reduced sensitivity (e.g., ~84.2%) and instances of false positives or species misclassification, and it states RDT positives must be confirmed by microscopy where possible.

For malaria, the policy specifies that rapid diagnostic tests (RDTs) alone are insufficient for definitive diagnosis and management. RDT results should be confirmed promptly by smear microscopy to determine species and quantify parasitemia; microscopy should be available within hours and may be repeated up to three times within three days if initial smears are negative but clinical suspicion remains.

The policy discourages routine use of WNV PCR for immunocompetent patients because of low sensitivity at symptom onset; instead, serology (anti‑WNV IgM in serum or CSF) is preferred and PRNT may be used to confirm and resolve cross-reactivity. NAAT may be considered in immunocompromised patients or select early presentations where RNA detection is more likely.

No statements in this excerpt explicitly label services as universally "not medically necessary." The excerpt includes citations and references supporting the guidance and notes the policy effective date 7/1/2023; determinations about medical necessity are applied via the enumerated coverage statements and the listed disallowed test items.

Provider Requirements, Documentation, and Operational Notes

Prior Authorization

Benefit Verification and Prior Authorization

Benefit-dependent prior authorization — Prior authorization requirements depend on the member's individual benefit coverage. Verify the member's benefits at the time of request and obtain any required prior authorization before ordering tests.

Check member benefits and applicable Medicare/Medicaid LCD/NCD guidance at time of service.

Documentation Required

Clinical Justification for Molecular and Rapid Assays

Molecular and rapid assay use should be clinically justified — Use of NAAT/molecular assays and rapid diagnostic tests (e.g., rapid malaria antigen tests) should be supported by clinical indication, timing of illness, and specimen appropriateness. Prefer tests with demonstrated sensitivity/specificity for the clinical context.

Use NAAT/PCR early for organisms where viremia/bacteremia is time-limited (see timing notes).

Epidemiology and Clinical Background

Background: Arthropod vectors (mosquitoes, ticks, fleas, mites) transmit a range of pathogens — bacteria, protozoa, and viruses — that cause illnesses such as Zika, West Nile virus, Rocky Mountain spotted fever (RMSF), Lyme disease, babesiosis, and malaria. Diagnostic approaches vary by organism and include culture, microscopy, NAAT/PCR, and serology; timing of specimen collection relative to symptom onset influences test performance and interpretation.

Key Terms and Test Modalities

inv-39: IFA — Indirect immunofluorescence antibody assay

DefinitionIndirect immunofluorescence antibody assay (IFA): a serologic assay used to detect IgG and IgM antibodies against pathogens.

Clinical noteIFA is the standard reference for many tickborne rickettsial infections but is insensitive during the first week of illness; paired acute and convalescent samples (2–4 weeks) and demonstration of a ≥4‑fold rise in titer are required for confirmation.

LimitationsIFA can cross‑react with prior vaccination or infection and elevated titers alone are insufficient to diagnose acute rickettsial infection.

inv-40: NAAT — Nucleic acid amplification testing (including PCR, RT-PCR, qPCR)

DefinitionNucleic acid amplification testing (NAAT): laboratory methods including PCR, RT‑PCR, and qPCR to detect pathogen DNA or RNA.

Performance

Coding and Billing Notes

Coding note: The policy excerpt does not provide explicit code groups. Coverage determinations and the enumerated accepted or disallowed test modalities described above should be used to inform code-table population and mapping (for example, mapping smear microscopy, NAAT/PCR, IFA IgG/IgM, RDTs, and PRNT to appropriate CPT/HCPCS and laboratory test codes where applicable). Ensure codes reflect the covered methods and note disallowed tests to prevent inappropriate reimbursement.

References and Policy Adoption

2023-07-01Adoption/Effective dateLatest

Policy adopted per Avalon recommendation with an effective date of 7/1/2023.

2017-10-31Reference added

WHO Plague guidance (WHO Plague) included in references supporting diagnostic recommendations.

2018-05-29Reference added

Policy Summary

PayerBlue Cross Blue Shield - Tennessee

PolicyTesting for Mosquito- or Tick-Related Infections — Coverage Criteria

Policy CodePolicy N/A

Change TypeNo material changes

Effective DateJul 1, 2023

Next Review DateN/A

Key ActionSelect diagnostic tests by pathogen and specimen type and document specimen timing and clinical signs to support coverage.

SourceLink

On This Page

Each febrile bout lasts 3–12 days; microscopy may detect spirochetes

Babesiosis: Preferred diagnostic tests are blood smear (Giemsa/Wright) and PCR for Babesia DNA; serology may be adjunctive but is less useful acutely and not recommended as sole acute diagnostic.

Consider reference lab confirmation; immunocompromised patients may have relapsing disease

Malaria: Microscopic blood smear (thick and thin) and antigen RDTs are common; NAAT/PCR is more sensitive for low parasitemia and for species identification and is a recommended adjunct when clinical suspicion exists, but is not preferred for immediate acute management.

BinaxNOW has lower sensitivity in nonendemic areas and can misclassify species

Arboviruses (WNV, Dengue, Yellow fever, Chikungunya): Serologic assays (IgM capture ELISA/IFA) are primary for many arboviruses; PCR/antigen detection (e.g., dengue NS1, RT-PCR) is useful early in illness or in immunocompromised patients; cross-reactivity among flaviviruses may require PRNT for confirmation.

Neuroinvasive WNV requires CSF testing; consider specialty/reference lab or public health submission

Direct microscopic observation (darkfield or stained thin/thick smears) is useful early due to high spirochetemia; serology is not standardized—obtain convalescent serum ≥21 days after onset for comparison and consider reference lab confirmation.

≥21 days for convalescent sample

High spirochetemia aids microscopy

Babesiosis: Manual review of blood smears (Giemsa/Wright) should be requested for acute symptomatic patients; multiple smears may be needed; NAAT is a primary test for acute infection in some contexts; serology (acute and convalescent IFA) is not recommended for acute diagnosis but can aid in low parasitemia or differentiation from Plasmodium.N/A

Consider reference lab confirmation

Malaria: Smear microscopy of Giemsa-stained thick and thin films is the gold standard; repeat every 12–24 hours for up to three exams (24–72 hours) before ruling out malaria; RDTs may be used where microscopy is unavailable but require confirmation by microscopy within 12–24 hours; PCR is sensitive for speciation and mixed infections but is not timely for acute management.3 exams over 24–48 h (up to 72 h)

Microscopy required urgently

Arboviruses (WNV, dengue, YFV, chikungunya): Diagnosis varies by agent: NAAT/virus isolation is useful early for YFV, chikungunya, and dengue; IgM serology (serum/CSF) is the mainstay for WNV and many arboviruses; cross-reactivity among flaviviruses may necessitate PRNT for confirmation and repeat convalescent sampling when acute-phase testing is negative.2–3 weeks between sera for PRNT confirmation

Consider public health submission for certain viruses

Perform PCR within the first week for anaplasmosis and ehrlichiosis because doxycycline therapy rapidly decreases PCR sensitivity; serology requires paired acute/convalescent specimens (2–4 weeks) and a fourfold rise in IgG for confirmation.

PCR within first week; paired sera 2–4 weeks apart

AAP guidance; negative PCR after treatment does not exclude infection

Malaria and babesiosis diagnostics: Microscopic examination of thick and thin blood films is primary for malaria and babesiosis; request manual (nonautomated) smear review for babesiosis; repeat smears every 12–24 hours up to 72 hours if suspicion persists despite initial negative smears.repeat smears every 12–24 hours up to 72 hours if initial negative and suspicion remains

AAP guidance; repeat microscopy allowance up to 3 times

RDTs are acceptable when immediate microscopy is unavailable but have limitations (species ID, quantitation, sensitivity).

Documentation Required

Timely Malaria Microscopy Required

Immediate microscopy for suspected malaria — When malaria is suspected, perform smear microscopy immediately and ensure results are available within hours. Do not batch microscopy or routinely send smears to reference labs if delayed results would affect acute management.

Microscopy should determine species, life-cycle stage, and parasitemia and be completed by experienced microscopist when possible.
If microscopy is unavailable, RDT may be used as an adjunct but should be confirmed by microscopy as soon as possible.

Note

Prior Authorization (Policy-level)

Prior authorization — none stated in excerpt — This policy section does not specify any additional prior authorization programs beyond benefit-dependent requirements; follow payer-specific prior authorization processes if applicable.

If a payer-specific prior authorization program exists, follow that program.
No procedure-specific step therapy or quantity limits are stated in this section.

Documentation Required

Specimen Type and Test Sensitivity

Testing performed on an inappropriate sample type may reduce sensitivity — Select specimen type based on pathogen and test modality (e.g., whole blood vs serum vs tissue vs CSF). Document specimen source; some pathogens (e.g., R. rickettsii) have higher PCR sensitivity from tissue than whole blood.

Choose sample type consistent with CDC and test manufacturer guidance.
Document specimen source in the record (whole blood, serum, CSF, tissue, etc.).

Note

Applicable State and Federal Regulations Take Precedence

Government policy precedence — If this Policy conflicts with applicable government policy (e.g., LCDs, NCDs, or state Medicaid rules), government policy prevails. Consult CMS and state Medicaid sources for up-to-date coverage rules.

Refer to the Medicare Coverage Database and applicable state Medicaid websites for definitive guidance.

Denial Risk

Procedural Denial Triggers

No procedural denial triggers are specified in this section — This section contains operational notes and reference material; it does not list specific procedural denial triggers beyond the general coverage criteria and documentation requirements.

Denials may occur if non-covered tests are ordered (see reimbursement policy lists) or if required documentation is missing.

Documentation Required

Document Clinical Indication and Benefit Verification

Benefit verification and clinical documentation — Apply coverage criteria based on the individual member's benefit coverage. Include clinical signs, symptoms, travel/exposure history, and rationale for test selection in the medical record to support medical necessity.

Document typical signs/symptoms (e.g., fever, headache, rash, travel, tick exposure) and test timing relative to symptom onset.
Include prior authorization reference if obtained.

Documentation Required

Specimen Timing and Paired Serology Documentation

Document sample type and timing (acute vs convalescent) — Record the specimen source and the timing of collection relative to symptom onset (acute vs convalescent). For serologic testing that requires paired sera, ensure documentation of dates for both acute and convalescent samples.

For tickborne rickettsial diseases and TBRF, collect an acute specimen early and a convalescent specimen 2–4 weeks later to demonstrate seroconversion or a fourfold rise in titer.
For arboviruses/WNV, consider repeat testing if initial serology is negative and clinical suspicion remains high.

Note

Reference: Mayo Clinic Laboratories Test ID (Malaria PCR)

Mayo Clinic Labs Test ID reference — The policy lists a Mayo Clinic Laboratories Test ID for malaria molecular PCR (LCMAL) as a referenced resource for molecular detection of Plasmodium species.

Test ID: LCMAL Malaria, Molecular Detection, PCR, Varies (Mayo Clinic Laboratories).

Documentation Required

Allowable Repeat Malaria Microscopy

Malaria repeat testing allowance — For suspected malaria with an initial negative microscopy, repeat smear microscopy may be performed up to three times within three days if clinical suspicion persists.

Repeat microscopy can be repeated up to three times within three days when initial microscopy is negative and clinical suspicion remains high.

Documentation Required

Select Testing Modality Appropriately

Select testing modality based on pathogen and clinical context — Choose culture, NAAT/RT‑PCR, serology, or microscopy according to pathogen biology, timing of illness, and purpose (clinical diagnosis vs epidemiology). Culture is often used for epidemiology or research and may be less sensitive/time‑consuming.

Culture may be required for certain organisms but is often less sensitive and slower than NAAT or serology.
Use tissue or biopsy specimens for improved PCR sensitivity for certain rickettsial infections when appropriate.

Documentation Required

Timing: NAAT Early, Serology for Later Confirmation

Use NAAT early, then serology as indicated — For many tickborne bacterial/intracellular infections and certain arboviruses, perform NAAT/PCR early in illness (often within first week) when nucleic acid is detectable; use serology (acute and convalescent) later to document seroconversion or rising titers.

For ehrlichiosis/anaplasmosis, perform PCR within the first week; doxycycline can reduce PCR sensitivity if started.
For arboviruses (e.g., WNV), serology (IgM) may be preferred for neuroinvasive disease because PCR in CSF is relatively insensitive; consider paired sera for confirmation.

Documentation Required

Document Timing Relative to Therapy

Timing relative to therapy — Document timing of specimen collection in relation to initiation of antimicrobial or antiviral therapy because treatment (e.g., doxycycline) can reduce PCR sensitivity. Negative PCR after treatment does not rule out infection.

Perform PCR testing before or very early after starting therapy when possible.
If antibiotics were started prior to specimen collection, note this in documentation as it may affect test sensitivity.

NAATs are generally specific and sensitive and can be applied to serum, whole blood, tissue, CSF, and FFPE samples; availability and cost vary by laboratory.

Use casesSome NAATs are available as rapid diagnostic tools but may not be available at all laboratories; specimen type influences sensitivity.

inv-41: NAAT — Nucleic acid amplification testing used to detect pathogen DNA/RNA with high sensitivity and specificity

DefinitionNAAT (PCR/RT‑PCR): molecular assays to detect pathogen nucleic acid with high sensitivity and specificity when appropriate sample types are used.

Specimen considerationsSensitivity varies by sample and pathogen (e.g., whole blood PCR for R. rickettsii is less sensitive than tissue PCR); choose specimen per organism guidance.

Regulatory noteFDA has approved specific NAAT assays (e.g., Rickettsia Real‑Time PCR K170940); many NAATs/LDTs require local validation under CLIA.

inv-42: IFA — Indirect immunofluorescence antibody assay used to detect IgG/IgM antibodies; cross‑reactivity may occur and acute/convalescent comparison is often required

DefinitionIndirect immunofluorescence antibody assay (IFA) for IgG/IgM: serologic method to detect virus- or bacteria‑specific antibodies in serum or CSF.

Cross-reactivity and timingIFA can cross‑react with prior vaccination or other flavivirus infections; antibody detection is often delayed (IgM/IgG appear after the first week), so acute and convalescent comparison is frequently required.

Diagnostic roleFor many arboviruses and rickettsial diseases, IFA/serology is the mainstay because viremia may be transient; confirmatory testing (e.g., PRNT) may be needed when cross‑reactivity is a concern.

inv-43: IFA — Reference standard for many tickborne rickettsial infections but insensitive during the first week of illness

Reference standardIFA is considered the standard reference serologic assay for many tickborne rickettsial infections.

Sensitivity limitationIFA assays are typically insensitive during the first week of illness; an acute specimen and a convalescent specimen 2–4 weeks later are recommended to demonstrate seroconversion or a fourfold rise in titer.

Culture noteRickettsiae are obligate intracellular organisms and cannot be isolated by standard blood culture techniques; specialized methods are required.

inv-44: Microscopy (blood smear) — Light-microscopic examination (thin and thick smears) considered gold standard for malaria and primary diagnostic for babesiosis and TBRF

DefinitionMicroscopy (blood smear): light‑microscopic examination of thick and thin Giemsa-/Wright‑stained blood smears to detect parasites or organisms.

Gold standard usesBlood‑smear microscopy is the gold standard for malaria diagnosis and is the primary diagnostic method for babesiosis and for detecting spirochetemia in tick‑borne relapsing fever when organisms are present.

Operational noteManual, experienced microscopist review is recommended; multiple smears may be needed and timely results (within hours) are critical for acute malaria management.

inv-45: Serologic testing — Detection of virus-specific IgM and/or IgG antibodies in serum and/or CSF; preferred for most arboviruses given timing of viremia and antibody response

DefinitionSerologic testing: detection of virus‑specific IgM and/or IgG antibodies in serum and/or CSF (e.g., ELISA, IFA, MAC‑ELISA).

Preferred use for arbovirusesFor most arboviruses, serology (IgM/IgG) of serum and CSF is preferred because viremia is often low or transient; CSF IgM is more sensitive than PCR for neuroinvasive WNV.

CaveatsArboviral IgM may persist for many months and cross‑react with other flaviviruses or prior vaccination; paired sera or PRNT may be needed to confirm recent infection.

inv-46: LDT (Laboratory-developed test) — Tests developed and validated in-house and regulated under CLIA as high-complexity tests

DefinitionLaboratory‑developed test (LDT): tests developed and validated in‑house and regulated under CLIA as high‑complexity tests.

Regulatory contextLDTs are not FDA‑approved or cleared but are permitted for clinical use when validated by the performing laboratory under CLIA requirements; documentation of validation may be requested.

Operational noteMany laboratories develop specific LDTs for organism detection and must perform local validation and maintain appropriate quality systems.

inv-47: Mayo Clinic Labs Test ID (LCMAL) — LCMA L Malaria, Molecular Detection, PCR reference

Test IDMayo Clinic Laboratories Test ID: LCMAL — Malaria, Molecular Detection, PCR (Molecular test catalog entry).

PurposeReferenced as an example molecular detection assay for Plasmodium species used in diagnostic and reference testing contexts.

SourceMayo Clinic Laboratories test catalog (LCMAL) cited in policy references.

Wolters Kluwer review on Rocky Mountain spotted fever referenced to support rickettsial disease diagnostic guidance.

2021-02-23Reference added

Wolters Kluwer dengue clinical manifestations and diagnosis reference included for arboviral diagnostic recommendations.

2014-01-01Reference added

Meatherall et al. (2014) BMC Infectious Diseases study on false positive malaria RDT cited in reference list.